Bio/Pharma News

Allergan Enters into CRISPR Territory with Editas Partnership

March 14, 2017

Under the agreement, Allergan will receive exclusive access to five of Editas’ ocular programs.

Chairman of Senate Judiciary Committee Raises Questions Over Auvi-Q Price Tag

March 09, 2017

Senator Chuck Grassley sent a letter to the Kaléo CEO questioning the drugs high listing price.

FDA Grants Clearance for Clinical Development of UCART19

March 09, 2017

The agency granted Pfizer, Cellectis, and Servier clearance to begin clinical development with UCART19.

MedImmune and Sanofi Pasteur Strike Deal

March 07, 2017

The companies have entered into an agreement to develop and commercialize a mAb for the prevention of lower respiratory tract illness in young children.

BeiGene and GDD Build Biologics Facility in China

March 07, 2017

BeiGene and the Guangzhou Development District have established a joint venture to build a biologics manufacturing facility in China.

Study Dismantles PhRMA’s Long-Standing Argument on Drug Pricing

March 07, 2017

A blog posted on Health Affairs on March 7, 2017 presents a study that tested PhRMA’s long-standing argument that high prices for drugs fund research and development in the pharmaceutical industry.

Sanofi and Lonza Partner on mAb Cell Culture Facility in Switzerland

February 27, 2017

Sanofi and Lonza formed a joint venture to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.

Sarepta Sells Priority Review Voucher to Gilead for $125 Million

February 24, 2017

Sarepta sold the priority review voucher for Exondys 51, a controversial treatment for Duchenne Muscular Dystrophy, to Gilead.

FDA Grants Pfizer Priority Review for Inotuzumab Ozogamicin

February 22, 2017

FDA granted inotuzumab ozogamicin priority review and accepted its BLA for filing.

CellGenix Adds Capacity for Cell Therapy Raw Materials

February 22, 2017

CellGenix will add R&D, production, and warehouse space in Freiburg, Germany for GMP-grade raw materials for cell therapy, gene-therapy, and tissue-engineered products.